It clearly shows Norvatis strategy is to focus on genes therapy and immutherapy. The are reducing exposure on infectious diseases.
IMP701 is in the hot space that they are trying to catchup!. There is no way they can afford to drop it IMO. In fact, I see an opportunity for Immutep to land a contract to manage IMP701’s development program.
Good time ahead for Immutep holders.
Novarits on the prowl,, page-20
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
0.020(7.02%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 31.0¢ | 29.0¢ | $1.171M | 3.900M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 101067 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 8068 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
